课题基金 / 基金详情

Project 1: Theranostics in Neuroendocrine Tumors

Project 1: Theranostics in Neuroendocrine Tumors
项目 1:神经内分泌肿瘤的治疗诊断学
批准号:
9149653
负责人:
Yusuf Menda
金额:
$28.43万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
3-Dimensional90YAdultAffinityAnimalsBindingBiodistributionBiopsy SpecimenChemicalsChildClinical TrialsCollaborationsCombined Modality TherapyCyclizationDataDevelopmentDiagnosisDiagnosticDiseaseDisease ProgressionDrug KineticsExternal Beam Radiation TherapyG-Protein-Coupled ReceptorsGastric Inhibitory PolypeptideGoalsHealthHumanImageIn VitroIncidenceIslet Cell TumorIsotopesLeadLigandsLysineMalignant NeoplasmsMelanocortin 1 ReceptorModelingModificationNeuroendocrine TumorsOctreotideOperative Surgical ProceduresOrphanOxytocinOxytocin ReceptorPancreasPatientsPatternPeptide LibraryPeptide ReceptorPeptidesPharmaceutical PreparationsPositron-Emission TomographyPre-Clinical ModelPrevalenceProcessPublicationsRadiation therapyRadiolabeledRadionuclide therapyRadiopharmaceuticalsReproducibilityResearchResidual stateResistanceSDZ RADSSTR2 geneSafetySerumSmall IntestinesSpecialized Program of Research ExcellenceSpecificitySpecimenTechniquesTestingTherapeuticTimeTissue MicroarrayTissuesToxic effectTracerUnited StatesVasoactive Intestinal Peptideanalogcandidate markerchemotherapycurative treatmentscytotoxicitydesigneffective therapyhigh throughput screeningimprovedin vivoinnovationinterestmeetingsmouse modelnovel diagnosticsnovel therapeuticspatient registrypre-clinicalradiotracerreceptorreceptor expressionrepositoryresearch clinical testingsomatostatin receptor 2targeted agenttargeted treatmenttheranosticstherapeutic targetthree-dimensional modelingtumortumor xenograftunnatural amino acidsvasoactive intestinal peptide receptor 1

项目摘要

项目成果

Yusuf Menda的其他基金

相似基金

相关文献

中文摘要
翻译
神经内分泌肿瘤(NETs)对儿童和成人构成了未被认识的健康威胁。发生率
英文摘要
Neuroendocrine tumors (NETs) constitute an unrecognized health threat to children and adults. The incidence and prevalence of NETs is rising in the United States; yet, there is very little research on NETs, and no effective treatment for patients with metastatic disease, over half of whom die within five years of diagnosis according to latest SEER data. These tumors do not respond to conventional chemotherapy or external beam radiation, making development of new diagnostic and therapeutic options imperative. We hypothesize that theranostics, use of a single compound as both a therapeutic and a diagnostic agent, will meet this critical need for children and adults with NETs. The translational component of this proposal will identify new theranostic targets, design and synthesize new targeting agents, and test their efficacy in vivo. Lead compounds that meet strict criteria as high affinity PET tracers and molecularly targeted therapeutic agents in pre-clinical models of bronchial, small bowel, or pancreatic neuroendocrine tumors will be brought forward to first in human PET imaging trials through an Exploratory IND mechanisms. Specific aims are: 1. Design and synthesize unique, high-affinity, stable ligands for use in GPCR targeted theranostics. Expression data from Project 3 has identified three GPCR (OXTR, VPAC1, MC1R) as new targets in NETs. Theranostic radiopharmaceuticals will be designed and synthesized using NMR and 3-D modeling to guide chemical modifications that enhance affinity, specificity and stability of candidate ligands. Peptide libraries incorporating D- and unnatural amino acids, cyclization strategies, and lysine substitutions for DOTA conjugation will be synthesized; binding affinity, specificity and stability will be determined in vitro. 2. Characterize in vivo specificity, stability, pharmacokinetics, and cytotoxicity of new GPCR targeted theranostic compounds in mouse models of neuroendocrine tumors. We will conduct theranostic pre- clinical in vitro and in vivo testing of lead GPCR targeted ligands in mouse models of NETs with the goal of having at least two analogs ready to test as PET tracers in humans by year 5. 3. Examine safety and efficacy of new GPCR targeted PET tracers in humans using exploratory IND. Agents that pass rigorous pre-clinical testing will then be synthesized under GMP conditions. An exploratory IND will be obtained to examine the ability of lead candidates to localize to neuroendocrine tumors in first in human trials. Successful tracers that meet the strict theranostic criteria and demonstrate safety, specificity, and reproducibility as a PET tracer in patients with NETs, will be further developed through a full IND. Successful completion of these pre-clinical theranostic trials and first in human molecularly targeted PET imaging trials will pave the way for development of new radiotherapeutics with the ultimate goal of providing dual-target, dual-radionuclide therapy for patients with neuroendocrine tumors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors
  • 批准号:
    10673599
  • 项目类别:
  • 资助金额:
    $50.31万
  • 财政年份:
    2019
  • 负责人:
    Yusuf Menda
  • 依托单位:
Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors
  • 批准号:
    10152579
  • 项目类别:
  • 资助金额:
    $60.66万
  • 财政年份:
    2019
  • 负责人:
    Yusuf Menda
  • 依托单位:
Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors
  • 批准号:
    10396517
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2019
  • 负责人:
    Yusuf Menda
  • 依托单位:
Project 1: Theranostics in Neuroendocrine Tumors
  • 批准号:
    10264528
  • 项目类别:
  • 资助金额:
    $5.86万
  • 财政年份:
    2015
  • 负责人:
    Yusuf Menda
  • 依托单位:
国内基金
海外基金
90Y联合Flt3L作为原位疫苗联合ICIs治疗HBV相关HCC机制研究
  • 批准号:
    82372067
  • 项目类别:
    面上项目
  • 资助金额:
    55万元
  • 批准年份:
    2023
  • 负责人:
    朱海东
  • 依托单位:
多功能90Y微球的构建及其在肝癌放射栓塞降期治疗中的应用研究
  • 批准号:
    22006109
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段广新
  • 依托单位:
90Y标记的EGFR mAb靶向性干预脊髓损伤后反应性胶质增生的实验研究
  • 批准号:
    30800340
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    22.0万元
  • 批准年份:
    2008
  • 负责人:
    田代实
  • 依托单位: